

COMBINED DECLARATION AND POWER OF ATTORNEY
FOR UTILITY PATENT APPLICATION

AS A BELOW-NAMED INVENTOR, I HEREBY DECLARE THAT:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if more than one name is listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: *GLYCOSYL SULFOTRANSFERASE-3* the specification of which

___ is attached hereto

X was filed on March 20, 1998.

and assigned Serial No. 09/045,284 and was amended on _____.

- 09076/086US1
SF-98-080
R0040A-ORD
- (a) A patent by its very nature is affected with a public interest. The public interest is best served, and the most effective patent examination occurs when, at the time an application is being examined, the Office is aware of and evaluates the teachings of all information material to patentability. Each individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability as defined in this section. The duty to disclose information exists with respect to each pending claim until the claim is canceled or withdrawn from consideration, or the application becomes abandoned. Information material to the patentability of a claim that is canceled or withdrawn from consideration need not be submitted if the information is not material to the patentability of any claim remaining under consideration in the application. There is no duty to submit information which is not material to the patentability of any existing claim. The duty to disclose all information known to be material to patentability is deemed to be satisfied if all information known to be material to patentability of any claim issued in a patent was cited by the Office or submitted to the Office in the manner prescribed by §§ 1.97(b)-(d) and 1.98. However, no patent will be granted on an application in connection with which fraud on the Office was practiced or attempted or the duty of disclosure was violated through bad faith or intentional misconduct. The Office encourages applicants to carefully examine:

- (1) prior art cited in search reports of a foreign patent office in a counterpart application, and
- (2) the closest information over which individuals associated with the filing or prosecution of a patent application believe any pending claim patentably defines, to make sure that any material information contained therein is disclosed to the Office.

- (b) Under this section, information is material to patentability when it is not cumulative to information already of record or being made of record in the application, and
- (1) It establishes, by itself or in combination with other information, a prima facie case of unpatentability of a claim; or
 - (2) It refutes, or is inconsistent with, a position the applicant takes in:
 - (i) Opposing an argument of unpatentability relied on by the Office, or
 - (ii) Asserting an argument of patentability.

A prima facie case of unpatentability is established when the information compels a conclusion that a claim is unpatentable under the preponderance of evidence, burden-of-proof standard, giving each term in the claim its broadest reasonable construction consistent with the specification, and before any consideration is given to evidence which may be submitted in an attempt to establish a contrary conclusion of patentability.

I do not know and do not believe this invention was ever known or used in the United States of America before my or our invention thereof, or patented or described in any printed publication in any country before my or our invention thereof or more than one year prior to said application. This invention was not in public use or on sale in the United States of America more than one year prior to this application. This invention has not been patented or made the subject of an inventor's certificate issued before the date of this application in any country foreign to the United States of America on any application filed by me or my legal representatives or assigns more than six months prior to this application.

I hereby claim priority benefits under Title 35, United States Code § 119(e)(1) of any United States provisional application(s) for patent as indicated below. I hereby claim benefit under Title 35, United States Code § 120 of any United States Patent application(s) listed below and, insofar as the subject matter of each of the claims of this application are not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, section 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulation, section 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application.

Application No.	Date of Filing (day/month/year)	Priority Claimed
		Yes ___ No ___

I hereby appoint the following attorneys and agents to prosecute that application and to transact all business in the Patent and Trademark Office connected therewith and to file, to prosecute and to transact all business in connection with all patent applications directed to the invention:

Dianne E. Reed, Reg. No. 31,292
Karl Bozicevic, Reg. No. 28,807
Kenneth Barovsky, Reg. No. 36,442
Bret E. Field, Reg. No. 37,620
Pamela J. Sherwood, Reg. No. 36,677

Carol L. Francis, Reg. No. 36,513
David W. Maher, Reg. No. 40,077
Carol M. Gruppi, Reg. No. 37,341
Dianna L. DeVore, Reg. No. P42,484
Michael A. Glenn, Reg. No. 30,176

Address all correspondence to: Bret E. Field at

BOZICEVIC & REED LLP
285 Hamilton Avenue, Suite 200
Palo Alto, CA 94301

Address all telephone calls to: Bret E. Field at (650) 327-3400.

This appointment, including the right to delegate this appointment, shall also apply to the same extent to any proceedings established by the Patent Cooperation Treaty.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under § 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

First Joint or Sole inventor:

Signature: Annette Bistrup Date 4/21/98

Full Name of Inventor: Annette Bistrup

Citizenship: Denmark

Residence: 340 Warren Drive, San Francisco, California 94131

Post Office Address: University of California, San Francisco

Lung Biology Center

1001 Potrero Avenue, Bldg. 1, Room 150

San Francisco, CA 94110

Second Joint inventor:

Signature: Steven D. Rosen Date 4/21/98

Full Name of Inventor: Steven D. Rosen

Citizenship: United States of America

Second Joint inventor:

Signature: _____ Date _____
Full Name of Inventor: Steven D. Rosen
Citizenship: United States of America
Residence: 828 Clayton Street, San Francisco, California 94117
Post Office Address: University of California, San Francisco
Lung Biology Center
1001 Potrero Avenue, Bldg. 1, Room 150
San Francisco, CA 94110

Third Joint inventor:

Signature: Stefan Hemmerich Date 5/27/98
Full Name of Inventor: Stefan Hemmerich (nmn)
Citizenship: Federal Republic of Germany
Residence: 2936-B Harper Street, Berkeley, California 94703
Post Office Address: Roche Bioscience
3401 Hillview Avenue
Palo Alto, CA 94304

09076-086US1-0322-0000